A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Public ClinicalTrials.gov record NCT07196644. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 100 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 50 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Study identification
- NCT ID
- NCT07196644
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2025
- Primary completion
- Nov 30, 2030
- Completion
- Nov 30, 2030
- Last update posted
- Aug 13, 2026
2025 – 2030
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beverly Hills Cancer Center /ID# 275465 | Beverly Hills | California | 90211 | Recruiting |
| City of Hope National Medical Center /ID# 275613 | Duarte | California | 91010 | Recruiting |
| Valkyrie Clinical Trials /ID# 275547 | Los Angeles | California | 90067 | Recruiting |
| Stanford University - Palo Alto /ID# 282083 | Palo Alto | California | 94304 | Recruiting |
| Yale University School of Medicine /ID# 275978 | New Haven | Connecticut | 06510 | Recruiting |
| Florida Cancer Specialists - North /ID# 277137 | St. Petersburg | Florida | 33705 | Recruiting |
| Northwestern University Feinberg School of Medicine /ID# 276436 | Chicago | Illinois | 60611-2927 | Recruiting |
| University of Chicago Medical Center /ID# 275342 | Chicago | Illinois | 60637 | Recruiting |
| START Midwest /ID# 276603 | Grand Rapids | Michigan | 49546 | Recruiting |
| Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999 | New York | New York | 10065 | Recruiting |
| Duke Cancer Institute /ID# 275604 | Durham | North Carolina | 27710 | Recruiting |
| SCRI Oncology Partners /ID# 275686 | Nashville | Tennessee | 37203 | Recruiting |
| Dell Seton Medical Center /ID# 276474 | Austin | Texas | 78701 | Recruiting |
| University of Texas - Southwestern Medical Center /ID# 276053 | Dallas | Texas | 75235 | Recruiting |
| The University of Texas MD Anderson Cancer Center /ID# 275663 | Houston | Texas | 77030 | Recruiting |
| South Texas Accelerated Research Therapeutics /ID# 276608 | San Antonio | Texas | 78229 | Recruiting |
| Start Mountain Region /ID# 276607 | West Valley City | Utah | 84119 | Recruiting |
| Virginia Cancer Specialists - Fairfax /ID# 276010 | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07196644, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07196644 live on ClinicalTrials.gov.